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The importance of cost considerations in preterm birth trials 
David M. Haas 
This is a mini commentary on TAJ Nijman et al., pp. 875–883: https://doi.org/10.1111/1471-0528.15625 
As evidence-informed healthcare continues to advance, understanding the complexities of cost-effective 
interventions becomes increasingly important. Both new innovations and traditional therapies are being 
considered through a lens of costs and benefits. This can be particularly difficult when it comes to 
preventive interventions, as the cost savings from prevention of later events can be difficult to calculate. 
This is true in obstetrics for the condition of preterm birth. Every year, an estimated 15 million babies 
are born preterm (before 37 completed weeks of gestation), with numbers rising (WHO Fact Sheet, 
Preterm Birth, Feb 2018). Although worldwide costs have been elusive to calculate, a recent UK study 
estimated societal costs from a preterm birth to adult life to be £2.946 billion (Mangham-Jeffries et al. 
Pediatrics 2009:123; e312–27).  
As investigators determine the most effective therapeutics to delay or prevent preterm birth, it is 
important to embed cost analyses within those trials. Such an analysis is presented in this issue of BJOG 
(Nijman et al. BJOG 2019;126:875–83). The study presents a planned secondary analysis of the APOSTEL 
III trial comparing nifedipine and atosiban as tocolytics for women with threatened preterm birth. As 
part of the authors’ societal perspective on costs up to 6 weeks postpartum, they included lost 
productivity of the parents, an important factor. They found that the costs in the nifedipine group were 
significantly lower, by almost €8,500. As expected, the costs were driven mainly by fewer admissions to 
the NICU in the nifedipine group. Interestingly, if admitted, the groups had similar length of NICU stays.  
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One of the perplexing and difficult to interpret findings of both the original trial and this cost analysis is 
the higher neonatal death rate seen in the nifedipine group in the trial. Initially, this might be suspected 
as a reason for the higher costs in the atosiban group, as more of those infants would be alive to incur 
NICU costs. However, the results showed that the median day of death for infants who died in the 
nifedipine group was later than for those who died in the atosiban group, bolstering the case that the 
NICU costs are for some reason higher for the newborns in the atosiban group. This bears further study. 
Additionally, the calculations did not extend beyond 6 weeks postpartum. Thus, the societal costs of lost 
productivity of the newborns who died were not taken into account, nor were the lifetime costs of 
potential long-term disability in the preterm infants who survived. 
The authors accounted for multiple factors to highlight the cost of treatment for threatened preterm 
labour in the trial. Their sensitivity analyses were well planned. It appears that nifedipine may result in 
lower costs for women with threatened preterm birth. How these calculations translate to other 
healthcare economies or to low- and middle-income countries (LMIC) is another question that will need 
to be addressed by the global maternity health community. As many of the countries with the highest 
preterm birth rates are LMICs (Blencowe et al. Lancet 2012:9;379:2162–72), incorporating cost analyses 
into preterm birth studies in LMICs will inform preterm birth prevention initiatives worldwide. Preterm 
birth remains one of the most critical and costly societal problems in maternal-child health. Gathering 
cost data as well as effectiveness data can help advance strategies to reduce preterm birth on a global 
scale.  
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